Introduction Institutional aCute decompensAted HeaRt FailUre RegiStry (ICARUS) will provide information on clinical characteristics, medical practice, patterns of treatment, and outcomes of patients hospitalized with Acute Decompensated Heart Failure (ADHF) in a hospital in a middle-income country. Objective Describe the methodological aspects, sociodemographic, and clinical characteristics of patients hospitalized with ADHF and their short-term outcomes. Method Prospective cohort of patients with ADHF from the emergency service of a cardiovascular center. Descriptive statistics were used to synthesize sociodemographic characteristics, clinical characteristics during hospitalization, and outcomes. Results 1595 patients with ADHF. The median age was 68 years (Q1=58; Q3=76), and 69.28% were men. The median hospital stay was six days (Q1=4; Q3=11), with an accumulative incidence (AI) for rehospitalization at 30 days of 8.70 % (95% CI 7.18 to 10.40%), in-hospital mortality AI of 4.33% (95% CI 3.38 to 5.44%), and a median change in the quality-of-life score like Minnesota Living with Heart Failure Questionnaire (MLHFQ) at 30 days of -20 points (Q1=-37; Q3=-5). At discharge, all patients had a percentage greater than 70% of the use of quadruple neurohormonal blockade therapy. Conclusions ICARUS is one of the first registries in Latin America since the indication of the use of SGLT2 inhibitors, evaluating the clinical and sociodemographic characteristics, treatment patterns, and outcomes of a preliminary cohort of 1595 patients hospitalized for ADHF. The results indicate that, at discharge, up to 82.79% of patients were receiving quadruple neurohormonal blockade therapy, which is considerably challenging to achieve in Latin America. Considering the results of the Safety, tolerability and efficacy of up-titration of Guideline-Directed Medical therapies for acute heart failure (STRONG-HF study), our study reinforces the benefit of discharge with Guideline-Directed Medical Therapy (GDMT) for heart failure from hospitalization. The use of GDMT for heart failure may have influenced our positive outcomes in terms of in-hospital mortality, improvement in quality of life, and the percentage of short-term rehospitalizations compared to similar cohorts.Proportion of HF drug group

中文翻译：

---

ICARUS 登记处：拉丁美洲国家单个中心首批 1595 例急性失代偿性心力衰竭病例的调查结果


简介 机构 aCute 代偿性 HeaRt FailUre RegiStry （ICARUS） 将提供有关在中等收入国家医院住院的急性失代偿性心力衰竭 （ADHF） 患者的临床特征、医疗实践、治疗模式和结果的信息。目的 描述 ADHF 住院患者的方法学方面、社会人口学和临床特征及其短期结果。方法 来自心血管中心紧急服务的 ADHF 患者前瞻性队列。描述性统计用于综合社会人口学特征、住院期间的临床特征和结果。结果 1595 例 ADHF 患者。中位年龄为 68 岁 （Q1=58;Q3=76），男性占 69.28%。中位住院时间为 6 天 （Q1=4;Q3=11），30 天再住院的累积发生率 （AI） 为 8.70%（95% CI 7.18 至 10.40%），院内死亡率 AI 为 4.33%（95% CI 3.38 至 5.44%），生活质量评分的中位变化，如明尼苏达心力衰竭患者问卷 （MLHFQ） 在 30 天时为 -20 分 （Q1=-37;Q3=-5）。出院时，所有患者使用四联神经激素阻断疗法的百分比大于 70%。结论 ICARUS 是自适应使用 SGLT2 抑制剂以来拉丁美洲最早的注册机构之一，评估了 1595 例因 ADHF 住院的患者的初步队列的临床和社会人口学特征、治疗模式和结果。结果表明，出院时，高达 82.79% 的患者正在接受四联神经激素阻断治疗，这在拉丁美洲实现相当具有挑战性。 考虑到指南指导的急性心力衰竭药物治疗（STRONG-HF 研究）上调的安全性、耐受性和有效性的结果，我们的研究加强了指南指导药物治疗 （GDMT） 出院对住院心力衰竭的益处。与类似队列相比，使用 GDMT 治疗心力衰竭可能影响了我们在院内死亡率、生活质量改善和短期再住院百分比方面的积极结果。HF 药物组比例